SPY314.07+3.55 1.14%
DIA260.22+2.91 1.13%
IXIC10,270.01+115.38 1.14%

SCYNEXIS Says Second Phase 3 Study Of Ibrexafungerp On Track For Top-Line Results In Early Q2'20, Supporting NDA Submission In H2'20

Benzinga · -